Company: VRCA
Filing Date: 2025-12-23
Form Type: 424B3
Source: 0001193125-25-330986
Chunk: 8

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-23
Form: 424B3
Chunk 8
---
 actual future results may be materially different from what we expect. We qualify all of the forward-looking
statements in the foregoing documents by these cautionary statements.

5

USE OF PROCEEDS

We will not receive any of the proceeds from the sale or other disposition of the Resale Shares by the selling stockholders pursuant to this
prospectus. However, we would receive proceeds from any cash exercise of the Pre-Funded Warrants or Common Warrants as follows: (i) if any Pre-Funded Warrants are
exercised for cash, the exercise price of $0.0001 per share; and (ii) if any Common Warrants are exercised for cash, the exercise price of $6.315 per share.

We will bear the out-of-pocket costs, expenses and fees
incurred in connection with the registration of the Resale Shares to be sold by the selling stockholders pursuant to this prospectus. Other than registration expenses, the selling stockholders will bear underwriting discounts, commissions, placement
agent fees or other similar expenses payable with respect to sales of Resale Shares.

6

SELLING STOCKHOLDERS The selling stockholders may sell some, all or none of their Resale Shares. We do not know how long the selling stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale or other disposition of any of the Resale Shares. The Resale Shares covered hereby may be offered from time to time by the selling stockholders. As a result, we cannot estimate the number of shares of common stock each of the selling stockholders will beneficially own after termination of sales under this prospectus. In addition, the selling stockholders may have sold, transferred or otherwise disposed of all or a portion of its shares of common stock since the date on which it provided information for the table below. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to our common stock. Generally, a person “beneficially owns” shares of our common stock if the person has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to acquire voting or disposition rights within 60 days. The information in the table below and the footnotes thereto regarding shares of common stock to be beneficially owned after the offering assumes the sale of all shares being offered by the selling stockholders under this prospectus,